SCHEMBL25313410

SCHEMBL25313410

O=C1CC[C@@H](CNC2(c3ccc(F)cc3)CCCC2)N1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KCNA5 P22460 6/20 0.40
▸ NR1D2 Q14995 1/20 0.39
▸ CRBN Q96SW2 5/20 0.37
▸ DDB1 Q16531 3/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ JAK1 P23458 1/20 0.37
▸ TYK2 P29597 1/20 0.37
▸ JAK3 P52333 1/20 0.37
▸ CD274 Q9NZQ7 4/20 0.36
▸ PDCD1LG2 Q9BQ51 3/20 0.36
▸ TACR1 P25103 1/20 0.36
▸ PDCD1 Q15116 1/20 0.35
▸ HDAC3 O15379 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC2 Q92769 1/20 0.34
▸ HDAC6 Q9UBN7 1/20 0.34
▸ SLC6A4 P31645 1/20 0.34
▸ SLC6A3 Q01959 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25313374 1.00 KCNA5 (0.40) KCNA5NR1D2CRBNDDB1JAK2
SCHEMBL25311371 0.86 CD274 (0.36) CRBNCD274PDCD1LG2PDCD1
SCHEMBL25313884 0.86 CD274 (0.36) CRBNCD274PDCD1LG2PDCD1
SCHEMBL25313699 0.86 CD274 (0.38) CRBNDDB1CD274PDCD1LG2PDCD1
SCHEMBL25310838 0.86 CD274 (0.38) CRBNDDB1CD274PDCD1LG2PDCD1
SCHEMBL25311117 0.77 CD274 (0.38) CRBNDDB1CD274PDCD1LG2PDCD1
SCHEMBL30482532 0.77 CD274 (0.38) CRBNDDB1CD274PDCD1LG2PDCD1
SCHEMBL30482549 0.77 CD274 (0.38) CRBNDDB1CD274PDCD1LG2PDCD1
SCHEMBL25315591 0.77 CD274 (0.38) CRBNDDB1CD274PDCD1LG2PDCD1
SCHEMBL25309676 0.74 CD274 (0.37) CD274PDCD1LG2PDCD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240034717-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2024-02-01 — — US claimed
EP-4217065-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Saniona A/S (DK) 2023-08-02 — — EP claimed
CN-116368112-A Novel potassium channel inhibitors 萨尼奥纳有限责任公司 2023-06-30 — — CN claimed
WO-2022063767-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2022-03-31 — — WO claimed
US-20240034717-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2024-02-01 — — US disclosed
EP-4217065-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Saniona A/S (DK) 2023-08-02 — — EP disclosed
CN-116368112-A Novel potassium channel inhibitors 萨尼奥纳有限责任公司 2023-06-30 — — CN disclosed
WO-2022063767-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2022-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240034717-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 KCNA5 31/4885NR1D2 2040/4885CRBN 3618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback